Newton, MA & Wädenswil, Switzerland – September 16, 2026— GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the appointment of Andrea Matthews as Chief Business Officer. “We are delighted to welcome Andrea to GlycoEra’s leadership team,” said Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra....

Dr. Duda to apply deep expertise in rare and immune-mediated diseases   Newton, MA & Wädenswil, Switzerland – January 8, 2026 — GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders, today announced the appointment of Petra Duda, M.D., Ph.D., as Chief Medical Officer. Dr. Duda brings more than 20 years of global leadership in...

Financing led by Novo Holdings with significant support from world-class group of existing and new investors  Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated precision immunology pipeline    Newton, MA & Wädenswil, Switzerland – May 27, 2025– GlycoEra AG, a...